West Pharmaceutical opens the week with clear analyst consensus, shares hold near recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:27.

West Pharmaceutical Services (US9553061055) opens the new trading week on the NYSE with a solid post-earnings backdrop and a clear view from Wall Street analysts. The focus remains on the first quarter 2026 beat and how consensus targets position the shares versus recent levels, according to MarketBeat data.

What recent earnings showed

On April 23, 2026, West Pharmaceutical reported first quarter 2026 earnings per share of 2.13 dollars, clearly above the consensus expectation of 1.68 dollars per share compiled by MarketBeat. The upside surprise of 0.45 dollars per share underscores resilient demand for the company’s drug packaging and delivery solutions.

Revenues for the same quarter were reported at around 795 million dollars, reflecting solid demand trends despite a mixed macro backdrop in global healthcare spending. This revenue print provides context for why many analysts maintain constructive views on the stock, even after a strong multi-year performance.

How analysts frame the stock

Analysts tracking West Pharmaceutical generally categorize the stock as a quality compounder in the global injectable drug packaging and delivery segment, with peers including players in medical technology and healthcare supplies such as Becton Dickinson and Thermo Fisher Scientific. Bitget data indicates that roughly 60 percent of around 15 tracked analysts rate the shares as Buy or equivalent, while around 40 percent sit at Hold or Neutral, with very few explicit Sell calls.

The same compilation references a 12-month average target price range between roughly 365 and 380 dollars, suggesting room above the latest quoted levels near 330 dollars in late April 2026. Some more optimistic houses, including Jefferies in prior updates, have mentioned targets closer to 415 dollars, driven by expectations of faster margin improvements in higher-value proprietary components.

What the company sells

West Pharmaceutical earns most of its revenue from high-value injectable packaging and delivery components. A representative product line is its proprietary elastomer stoppers and seals used with prefilled syringes and vials, which support reliable storage and administration of biologic and small-molecule medicines for pharmaceutical customers worldwide.

Where the stock trades today

The West Pharmaceutical shares (US9553061055) trade on the NYSE under the ticker WST. As of 2026-04-22, 15:59 Eastern, MarketBeat reports a regular-session price of 329.52 dollars, with extended trading later that day showing 328.25 dollars for the shares.

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Data and assessments are based on sources cited and may change over time.